Takeda Pharmaceutical Company Limited http://www.takeda.com/ R&D News Takeda Pharmaceutical Company Limited http://www.takeda.com/ http://www.takeda.com/favicon.ico icon Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult WomenSucampo Pharmaceuticals’ Second Consecutive Successful FDA Approval for AMITIZA; 8 mcg Dose to Fill the Void in the Currently Available Therapies for IBS-C in Adult Women http://www.takeda.com/press/article_29496.html Bethesda - Maryland, Deerfield – Illinois, and Osaka - Japan --- Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Sucampo Pharmaceuticals’ supplemental New Drug Application (sNDA) for AMITIZA® (lubiprostone) 8 mcg capsules twice daily to treat Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years of age and older. As a result of this sNDA approval, Sucampo Pharmaceuticals will receive a development milestone payment of $50 million from Takeda in accordance with the Collaboration and License Agreement dated October 29, 2004 between Sucampo Pharmaceuticals and Takeda to jointly market AMITIZA in the United States and Canada. 2008-04-30 Presentation Materials about Acquisition of Millennium Pharmaceuticals, Inc. http://www.takeda.com/investor-information/presentations-events/article_19507.html 2008-04-10 Takeda to Acquire Millennium for Us$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion-- Acquisition Accelerates Takeda’s Vision of Becoming a Global Leader in Oncology -- http://www.takeda.com/press/article_29371.html OSAKA, Japan, and CAMBRIDGE, Mass., USA, April 10, 2008 –Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The transaction was unanimously approved by the Boards of Directors of both companies. Upon completion of the acquisition, Millennium will become a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and will continue operations in Cambridge, Massachusetts, as a standalone business unit. Millennium will be known as Millennium Pharmaceuticals, Inc., a Takeda Company. 2008-04-10 Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS® http://www.takeda.com/press/article_29309.html Osaka, Japan and Deerfield , Ill. (April 4, 2008) – Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. (“TPNA”) announced today that, on March 31, 2008, the U.S. Supreme Court denied the Petition for a Writ of Certiorari by Alphapharm Pty Ltd[ * ]. 2008-04-04 Launch of Takeda Bio Development Center Limited http://www.takeda.com/press/article_29225.html Osaka, Japan, April 1, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced the launch of Takeda Bio Development Center Limited (“Takeda Bio”). 2008-04-01